A phase III multicentre randomised clinical trial comparing gemcitabine alone or in combination with capecitabine for the treatment of patients with advanced pancreatic cancer.
|III||Treatment||Closed||N/A||Isrctn No: 11513444|
Pancreatic cancer represents one of the most important oncological challenges. This is reflected in the poor overall one-year survival of around 10% and long-term survival of only 0.4% 1. It is one of the top ten causes of cancer death in the Western world and is responsible for 6,000 deaths per year in the UK and around 40,000 per year in Europe 2,3
Trial Not Open
1. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995; 82(1):111-115.
2. Office for National Statistics. Cancer Survival Trends in England & Wales 1971-1995. 1999. Office for National Statistics.
3. HMSO. Great Britain Office of Population Censuses and Surveys: Cancer Statistics. 2000. HMSO. 1998
0151 794 8936
Sorry there are currently no job vacancies
Some useful downloads: